Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Kriegsmann, Katharina [VerfasserIn]   i
 Dittrich, Tobias [VerfasserIn]   i
 Neuber, Brigitte [VerfasserIn]   i
 Awwad, Mohamed [VerfasserIn]   i
 Hegenbart, Ute [VerfasserIn]   i
 Goldschmidt, Hartmut [VerfasserIn]   i
 Hillengaß, Jens [VerfasserIn]   i
 Hose, Dirk [VerfasserIn]   i
 Seckinger, Anja [VerfasserIn]   i
 Müller-Tidow, Carsten [VerfasserIn]   i
 Ho, Anthony Dick [VerfasserIn]   i
 Schönland, Stefan [VerfasserIn]   i
 Hundemer, Michael [VerfasserIn]   i
Titel:Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma
Verf.angabe:Katharina Kriegsmann, Tobias Dittrich, Brigitte Neuber, Mohamed H. S. Awwad, Ute Hegenbart, Hartmut Goldschmidt, Jens Hillengass, Dirk Hose, Anja Seckinger, Carsten Müller‐Tidow, Anthony D. Ho, Stefan Schönland,and Michael Hundemer
E-Jahr:2018
Jahr:25 March 2018
Umfang:10 S.
Fussnoten:Gesehen am 29.10.2019
Titel Quelle:Enthalten in: Cytometry. Part B, Clinical cytometry
Ort Quelle:Hoboken, NJ : Wiley-Liss, 2003
Jahr Quelle:2018
Band/Heft Quelle:94(2018), 5, Seite 767-776
ISSN Quelle:1552-4957
Abstract:Background Recent approaches in multiple myeloma (MM) treatment have targeted CD38. As antigen expression levels on plasma cells (PCs) were demonstrated to affect response to monoclonal antibody (mAb) treatment, a precise characterization of PC phenotype is warranted. Methods Anti-CD38 mAb (isatuximab) was tested for antibody-dependent cellular cytotoxicity (ADCC) in MM cell lines. Quantification of the number of sites (NOS) of CD38 on bone marrow PCs and other immune cells obtained from light chain (AL) amyloidosis (n = 46) and smoldering multiple myeloma (SMM) patients (n = 19) was performed with two different quantitative flow cytometry (QFCM) applications. Results ADCC activity of isatuximab was observed in cell lines with >100 × 103 CD38-NOS only. The average PC CD38-NOS was 153 ± 53 × 103 in AL amyloidosis and 138.7 ± 53 × 103 in SMM patients. Eight (17%) AL amyloidosis and 4 (21%) SMM patients showed a PC CD38-NOS level <100 × 103. In four AL amyloidosis and two SMM patients <10% of PCs had a CD38-NOS ≥100 × 103. The CD38-NOS identified on bone marrow lymphocytes, monocytes, and granulocytes was two log units below the CD38-NOS on PCs (P < 0.001). No significant differences in CD38-NOS expression levels on any of the analyzed PC subpopulations in AL amyloidosis and SMM patients were identified. Conclusion Levels of CD38 expression affect the isatuximab-mediated ADCC in vitro. As PCs of patients with AL amyloidosis and SMM do not homogenously express high CD38 our data provide a rationale for assessment of CD38-NOS in patients with PC disorders prior to anti-CD38 treatment. © 2018 International Clinical Cytometry Society
DOI:doi:10.1002/cyto.b.21636
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1002/cyto.b.21636
 Verlag: https://www.onlinelibrary.wiley.com/doi/abs/10.1002/cyto.b.21636
 DOI: https://doi.org/10.1002/cyto.b.21636
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:CD38 sites
 isatuximab
 quantitative flow cytometry
K10plus-PPN:1680559524
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68447504   QR-Code
zum Seitenanfang